Vibhudutta Awasthi, Ph.D.

Professor and Associate Dean for Research

Pharmaceutical Sciences

Phone (405) 271-6593 x47331

Fax (405) -271-7505

Office CPB 309

Email vibhudutta-awasthi@ouhsc.edu


Summary


My research interests are in the development of radiopharmaceuticals, small animal imaging and use of radiological imaging techniques to answer physiological questions. My current research focuses on the development of liposome encapsulated hemoglobin as an artificial oxygen carrier and he is studying cerebral oxygen metabolism using positron emission tomography. I am a board certified nuclear pharmacist with expertise in areas related to drug delivery, formulation development, nuclear pharmacy and small animal nuclear imaging.



Publications & Presentations

<< 1 2 3 4 5 > >>
    6. Awasthi V, Eeda V. A Catalyst-Free and Scalable Process for Synthesis of Novel MAP4K4 Inhibitor DMX-5804 and its Glyco-Conjugates. Organic Process Research & Development. 2021; 25 : 1658–1663

    7. Awasthi V, Sahoo K. Differential oxidative and pro-apoptotic response to an anti-inflammatory agent CLEFMA. BioRxiv . 2021

    8. Awwad H O, Hedrick A, Mdzinarishvili A, Houson H, Standifer K, Awasthi V. Modeling traumatic brain injury combined with hemorrhagic shock in rats: Neurological assessment and PET imaging with 18F-fluorodeoxyglucaric acid. . BioRxiv . 2021

    9. Awasthi V, Vilekar P, Rao G, Awasthi S. Anti-inflammatory mediators ST2 and SIGIRR are induced by diphenyldifluoroketone EF24 in lipopolysaccharide-stimulated dendritic cells. Immunobiology. 2020; 225 : 151886

    10. Awasthi S, Rahman N, Rui B, Kumar G, Awasthi V, Breshears M, Kosanke S. Lung and general health effects of Toll-like receptor-4 (TLR4)-interacting SPA4 peptide. BMC pulmonary medicine. 2020; 20 : 179

<< 1 2 3 4 5 > >>



Grants

1 2 3 >>
    1. Developing PPARγ acetylation inhibitor for the treatment of aging-related conditions. NIH. Start Date: 2021. End Date: 2026.

    2. Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment. NIH. Start Date: 2021. End Date: 2026.

    3. SBIR Phase I: Early-Stage Development of GPPD for Fatty Liver. NIH.

    4. Surfactant protein-A regions as TLR4-immunomodulators. NIH. Start Date: 2017. End Date: 2023.

    5. STTR Phase I: Cardiotropic Atorvastatin Liposomes for Myocardial Reperfusion Injury. NSF. Start Date: 2023. End Date: 2021.

1 2 3 >>



Awards and Honors

                                                                                            1. USPTO. Patent application issued. Date: 2015.  

                                                                                            2. Journal of Pharmaceutical Sciences. Article selected as a featured research paper. Date: 2015.  

                                                                                            3. Robert Glenn Rapp Foundation. Presidential Professor . Date: 2013.  

                                                                                            4. Sandra K and David L Gilliland Chair in Nuclear Pharmacy . Date: 2012.  




Education

                                                                                            1.  Degree: Ph D. Sanjay Gandhi Postgraduate Institute of Medical Sciences . Date: 1994.  

                                                                                            2.  Degree: M. Pharm.. Dr. Hari Singh Gour Vishwavidyalaya, Sagar (Formerly, University of Sagar). Date: 1990.  

                                                                                            3.  Degree: B. Pharm. Dr. Hari Singh Gour Vishwavidyalaya, Sagar (Formerly, University of Sagar). Date: 1988.  




Administrative Assignments

                                                

    1. Role: Associate Dean. Scope: College. Description: Lead research enterprise of the College of Pharmacy. Represent the College at the HSC level. Mentor researchers. Date: 2020.

                                                

    2. Role: Director. Scope: University. Description: Direction and conduct of nuclear imaging services for biomedical investigators; Production of PET radiotracers for preclinical imaging and preparation for regulatory compliance for clinical applications; Consultations with researchers about imaging and tracer applications. Date: 2007.




External Connections and Partnerships


no results